diaDexus Names Jean-Frederic Viret, PhD, as CFO
diaDexus, a diagnostics company focused on patent-protected in vitro diagnostic products, has appointed Jean-Frederic Viret, PhD, as its chief financial officer (CFO), effective 1 February 2012. Viret joins diaDexus after 12 years in finance operations of diagnostic and biotechnology companies, where he participated in and directed over US$200m in equity, debt and other strategic financings.
Most recently, Viret was CFO at XDx, a diagnostics company, where he not only led multiple private financings, but also was involved in increasing insurance coverage by 30% from large private payers. Prior to XDx, he was at Anesiva, a specialty pharmaceutical company, where he served in several roles of increasing responsibilities, including CFO. In particular, he led due diligence for all of Anesiva’s public raises and debt facilities to support commercial expansion.
Previously, Viret was associate director of finance at Tularik, a biotech company that was acquired by Amgen. At Tularik, he was instrumental in integrating European operations. Prior to that, he worked for PricewaterhouseCoopers (PwC) on a variety of life science and venture capital accounts, primarily in financial audits but also with the emerging company services group.
Viret earned a MBA from Cornell University. He has a PhD in Molecular Biology from the Universite Louis Pasteur in Strasbourg, France and a BS in Engineering from the Institut National Polytechnique de Lorraine, in Nancy, France.